Biocept adds Linda Rubinstein and Antonino Morales to its Board of Directors alongside Sam Riccitelli named new Board Chairman

– USA, CA –  Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, today announces the appointment of Linda Rubinstein and Antonino Morales to its Board of Directors, effective immediately.

The company also named Director Samuel Riccitelli as Chairman of the Board, succeeding long-time Chair David Hale and interim Chair Faye Wilson, both of whom remain Directors.

Rubinstein and Morales each brings extensive financial expertise and leadership experience to the Board, supporting Biocept’s focus on strategic growth and the advancement of its oncology diagnostics franchise. With these two additions, Biocept’s Board will increase from seven Directors to nine.

“We are proud to expand and strengthen our Board of Directors with these new appointments, which we believe will support recent business momentum and guide our long-term success. Sam will provide strong governance, leadership and insight as Chairman, while Linda and Antonino bring fresh perspectives, diverse backgrounds and a wealth of valuable experience to the Board,” said CEO, Michael Nall.

He added: “We are especially grateful to David Hale for serving as our previous Chairman and to Faye Wilson for stepping up as interim Chair.”

About Linda Rubinstein

Rubinstein has over 30 years of financial and capital markets experience in life sciences and investment banking. As CFO of public and private companies, she has contributed to strategy and operations, executed financial transactions, and delivered corporate and investor positioning. Since 2010 she has been a partner at FLG Partners, where she provides financial and strategic consulting services to life science and other companies such as Apexigen, ArmaGen, Five Prime, Kezar Life Sciences, Ingenuity Systems, iPierian and True North. Previously, she was a Principal at RDJ Advisors. Rubinstein also served as Vice President and CFO at Solexa, a biotech company with a leading DNA sequencing platform for genetic analysis, where in 2006 she helped negotiate the sale to Illumina, a global leader in genomics.

About Antonino Morales

Morales is a CPA and brings more than 30 years of broad international executive leadership experience in financial consulting, business development, operations, regulatory compliance, and risk management. He has worked with leading organizations such as Citibank, Bank of America, Arthur Anderson, and Mazda North America, as well as with entrepreneurial start-ups. Most recently, Morales was president and CEO of Apoyo Financiero, Inc., a California-based Community Development Financial Institution where he led a major digital transformation of the business model resulting in increased sales and profit growth.

About Samuel Riccitelli

Sam Riccitelli was appointed to the Biocept Board of Directors in October 2020. He has more than 35 years of experience in the healthcare industry and currently serves as an independent consultant to healthcare companies and as a Director of OrthoPediatrics Corp.

“I am honored to have the opportunity to serve as Biocept’s Chairman of the Board,” said Sam Riccitelli. “The company is making remarkable strides in oncology diagnostics, especially in neuro-oncology with the recent launch of the CNSide cerebrospinal fluid assay to aid in the identification and management of brain metastases. This esteemed group of Directors, now with the addition of Linda and Antonino, is committed to furthering Biocept’s strategic growth initiatives and advancing its molecular diagnostic services, with the ultimate goal of helping to improve clinical outcomes for patients with cancer.”

About Biocept

Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept’s patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

For more information: https://biocept.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.